FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Priority Review for Seres BLA for c.diff Therapy

FDA accepts for priority review a Seres Therapeutics BLA for its investigational oral microbiome therapeutic SER-109 for preventing recurrent C. diffi...

latest-news-card-1
Federal Register

Workshop on PET Imaging in Alzheimers Patients

Federal Register notice: FDA announces an 11/17 public workshop entitled Quantitative Brain Amyloid PET Imaging in Patients with Alzheimers Disease....

latest-news-card-1
Human Drugs

ICH Presentation on Selective Safety Data Collection

The International Council for Harmonization posts a presentation outlining its finalized guidance entitled A Selective Approach to Safety Data Collect...

latest-news-card-1
Human Drugs

Positive Results in AZ Breast Cancer Trials

AstraZeneca reports positive results from two trials evaluating new breast cancer treatments.

latest-news-card-1
Federal Register

Rare Disease Endpoint Pilot Program

Federal Register notice: FDA launches a Rare Disease Endpoint Advancement Pilot Meeting Program.

latest-news-card-1
Federal Register

Guide on ANDA In Vitro Permeation Studies

Federal Register notice: FDA makes available a draft guidance entitled In Vitro Permeation Test Studies for Topical Products Submitted in ANDAs.

latest-news-card-1
Federal Register

ANDA Physicochemical/Structural Characterization Guide

Federal Register notice: FDA makes available a draft guidance entitled Physicochemical and Structural (Q3) Characterization of Topical Drug Products i...

latest-news-card-1
Human Drugs

Tremfya 80% Response Rate in Ulcerative Colitis: Janssen

Janssen Pharmaceutical says new data show that patients given Tremfya (guselkumab) saw a clinical response rate of about 80% in trial subjects with mo...

latest-news-card-1
Human Drugs

FDA Explains Why Zepzelca Will Not be Withdrawn

Responding to a petition seeking the removal of approval for Jazz Pharmaceuticals lung cancer drug Zepzelca, FDA explains why it doesnt agree with the...

Human Drugs

FDA Approves Biologic for Some Myelomas

FDA gives accelerated approval to Janssens teclistamab-cqyv for some adults with relapsed or refractory multiple myeloma.